RESUMEN
Comparative evaluation of bepotastine besilate versus olopatadine and ketorolac combination onupper tarsal conjunctival brush cytology in patients of vernal keratoconjunctivitis. This studywas a prospective, open label, randomized, comparative clinical study. 100 patients of vernalkeratoconjunctivitis between 6 to 20 years of age of either sex willing to give informed consentwere enrolled in the study. In Group 1, 50 patients received Bepotastine besilate (0.15%) eyedrops twice daily for 8 weeks whereas in Group 2, 50 patients received Olopatadine (0.2%) andKetorolac (0.4%) combination eye drops twice daily for 8 weeks. Upper tarsal conjunctival brushcytology for eosinophil count was done in both the drug groups during the baseline and at 8th weekduring the treatment. It was found that after the 2 months of drug therapy, patients in both thegroups showed reduction in the eosinophil count. However, there was no statistically significantdifference between the two treatment groups at the baseline and at 8th week. There was 32%reduction in group A versus 28% reduction in group B in eosinophil count at the end of 8th weekcompared to baseline. Both bepotastine besilate versus olopatadine and Ketorolac combinationwere found to be effective in reducing the eosinophil count in patients of VKC.
RESUMEN
Objective: Comparative evaluation of efficacy and safety ofBepotastine besilate versus Olopatadine and Ketorolaccombination in patients with vernal keratoconjunctivitis.Materials and Methods: This was a prospective, open label,randomized, comparative clinical study. Hundred patients ofvernal keratoconjunctivitis between 6 to 20 years of age ofeither sex willing to give informed consent were enrolled in thestudy. In Group 1, 50 patients received Bepotastine besilate(0.15%) eye drops twice daily for 8 weeks whereas in Group 2,50 patients received Olopatadine (0.2%) and Ketorolac (0.4%)combination eye drops twice daily for 8 weeks. Symptoms andsigns scoring of VKC were recorded on baseline and at thetime of follow up at 4 and 8 weeks. Safety assessments werealso done in both the drug groups during the study period forany serious adverse effects.Results: After the 2 months of drug therapy, patients in boththe groups showed improvement in the symptoms and signsscoring of VKC. However, there was no statistically significantdifference between the two treatment groups at 4th and 8thweek. Both the drugs were well tolerated without any seriousadverse effect.Conclusion: Both bepotastine besilate versus olopatadine andKetorolac combination ophthalmic solutions were found to beeffective in alleviating the clinical symptoms and signs of VKC.
RESUMEN
Ocular itching and redness adversely affect the quality-of-life of vernal keratoconjunctivitis (VKC) patients. The objective of thisstudy was to evaluate changes in VKC patient's quality-of-life (QOL). The present study was prospective, open label,randomized, comparative clinical study. Hundred patients of vernal keratoconjunctivitis between 6 to 20 years of age of eithersex willing to give informed consent were enrolled in the study. In Group A, 50 patients received Bepotastine besilate (0.15%)eye drops twice daily for 8 weeks whereas in Group B, 50 patients received Olopatadine (0.2%) and Ketorolac (0.4%)combination eye drops twice daily for 8 weeks. The Quality of Life Questionnaire (QUICK) is a reliable and validated which wasassessed at baseline and at the time of follow up at 8 weeks. QUICK Questionnaire scores range from 30 to 90 with higher valuesrepresenting greater impairment. A decrease in QUICK Questionnaire score is clinically meaningful to the patients.The results showed that after the 2 months of drug therapy, patients in both the groups showed decrease in the quality of lifescoring of VKC. However, there was no statistically significant difference between the two treatment groups at 8th week. It maybe concluded that both bepotastine besilate versus olopatadine and Ketorolac combination ophthalmic solutions were found to beeffective in alleviating the clinical symptoms and signs of VKC. Hence, improving the quality of life of VKC patients.Keywords: Mast cell stabilizer, Topical NSAIDs, Newer H1-antihistaminics, Vernal keratoconjunctivitis, Quality of life
RESUMEN
Introduction: Radiation mitigators are the compounds whichcan minimize or ameliorate post irradiation-toxicity providedthey are administered before the onset of toxic symptoms.Hence, there is an urgent need to prevent harmful effectssecondary to ionizing radiations.Material and Methods: Sixty patients of Head and neckcarcinoma more than 18 years of age of either sex and willingto give informed consent were included in the study. In Group1, 30 patients received the Beclomethasone cream that wastopically applied from the day-1 of radiotherapy till 4-weeksafter completion of radiotherapy, whereas In Group-2, 30patients received the local application of the herbal paste fromthe day-1 of radiotherapy till 4-weeks after completion ofradiotherapy.Results: For measuring radiation-induced reactions, nonparametric test like chi-square test was applied and number ofpatients in different grades was calculated as per RTOGcriteria. Similarly for measuring radiation-induced mucosalreactions, chi-square test was applied and number of patientsin different grades was calculated as per RTOG-criteria.Conclusion: Present study revealed a marked beneficialeffects of herbal paste containing Azadirachta indica, aloevera, Ocimum sanctum and Curcuma longa on radiationinduced skin injury in patients with Head and neck carcinomaas compared to topical Beclomethasone cream.
RESUMEN
Radiation mitigators are the compounds which can minimize post irradiation-toxicity provided theyare administered before the onset of toxic symptoms. In present study we compared pre and posttreatment quality of life in head and neck cancer patients receiving radiotherapy.Sixty patients ofHead and neck carcinoma more than 18 years of age of either sex and willing to give informedconsent were included in the study. In Group-1, 30 patients received the Beclomethasone cream thatwas topically applied from the day-1 of radiotherapy till 4-weeks after completion of radiotherapy,whereas In Group-2, 30 patients received the local application of the herbal paste from the day-1 ofradiotherapy till 4-weeks after completion of radiotherapy. These 60 patients were evaluated at 6month post-therapy using the European organisation for research and treatment of cancer quality oflife questionnaire C30 .For measuring radiation-induced reactions, chi-square test was applied andnumber of patients in different grades was calculated as per Radiotherapy oncology group criteria.Similarly for measuring radiation-induced mucosal reactions, non-parametric test i.e chi-square testwas applied and number of patients in different grades was calculated as per radiotherapy oncologygroup criteria. As per quality of life questionnaire, evaluation on symptom scale revealed that fatigue,pain, dyspnoea, appetite loss and insomnia got worsened in Gp-1 patients, except for diarrhoea,constipation and nausea or vomiting while in Gp-2 patients, all symptoms showed improvement after6 month of completion of treatment. Comparing pre and post-treatment , the global health statusshowed statistically significant improvement in group-2 patients receiving polyherbal paste .The International Journal of Interdisciplinary and Multidisciplinary Studies (IJIMS), 2019, Vol 6, No.1,65-79. 66present study revealed a beneficial effects of polyherbal paste containing Azadirachta indica, aloevera, Ocimum sanctum and Curcuma longa on radiation induced skin injury in patients with Head andneck carcinoma as compared to topical Beclomethasone cream. Also there was improvement inquality of life in cancer patients receiving herbal paste measured at 6 month post-treatment.
RESUMEN
Dreams are a series of images, ideas, thoughts, emotions and sensations occurring involuntarily in the mind during certain stages of sleep. They have been described physiologically as a response to a neural process when the person is asleep while the psychological basis proposed is that they are because of reflection of the subconscious mind. Pharmacologists are of the view that medications, many hormones, neurotransmitters, herbs and supplements can alter dreams and make them more or less vivid.